BioCentury | Jan 9, 2020
Financial News

Aspect to engineer therapeutic tissues with $20M series A

...therapeutics. New investor Radical Ventures led the University of British Columbia spinout’s financing. Existing investors Pangaea...
BioCentury | Oct 20, 2017
Regulation

Realities of real-world evidence

...to treat chronic obstructive pulmonary disease (COPD), demonstrating the feasibility of premarket RWE research. (A) PANGAEA...
...target attainment at six months without documented symptomatic hypoglycemia 3,324 Sanofi (Euronext:SAN; NYSE:SNY) Jul 2018 PANGAEA...
BioCentury | May 30, 2016
Company News

Cancer Research UK, Pangaea Biotech deal

...Rac)-activated kinase (PAK) inhibitors for cancer. Both partners will be responsible for lead optimization, and Pangaea...
...future payments. The partners declined to disclose financial terms. Cancer Research UK , London, U.K. Pangaea...
BioCentury | Apr 15, 2013
Company News

Pangaea management update

Pangaea Pharmaceuticals Inc., Cambridge, Mass. Business: Cancer, Autoimmune/Inflammation, Infectious diseases/AIDS Hired: Mark Philip, Ph.D., as president and CEO; formerly president and CEO of Immuno-U.S. Inc. WIR Staff autoimmune cancer Infectious Inflammation...
BioCentury | Dec 20, 2010
Financial News

Semprus BioSciences completes venture financing

...12/13/10 Type: Venture financing Raised: $18 million Investors: SR One; Foundation Medical Partners; 5AM Ventures; Pangaea...
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Markers

...large-scale prospective study of transplant patients to identify candidates for a reduced regimen of immunosuppressants. Pangaea...
...Predicting allograft tolerance, page 7). SciBX 3(23); doi:10.1038/scibx.2010.719 Published online June 10, 2010 Patent pending; Pangaea...
BioCentury | Jun 10, 2010
Tools & Techniques

Predicting allograft tolerance

...that could help pinpoint transplant patients who may not need immunosuppressants. Miltenyi Biotec GmbH and Pangaea...
...said Pangaea CEO José Jimeno. "These patients will be more amenable to reducing immunosuppressant dosage." Pangaea...
...Bethesda, Md. King's College London , London, U.K. Miltenyi Biotec GmbH , Bergisch Gladbach, Germany Pangaea...
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Markers

...profile of tolerance and testing the effect of reduced dosing of immunosuppressants in those patients. Pangaea...
BioCentury | Mar 26, 2001
Company News

Infigen management update

...Wis. Business: Gene/Cell therapy Hired: Eric Postel as CFO, formerly senior partner and CFO at Pangaea...
BioCentury | Jun 28, 1999
Finance

It's all a matter of time

...of a capital infusion of CHF140 million ($93.7 million) in May, has added Zycos (formerly Pangaea...
Items per page:
1 - 10 of 24
BioCentury | Jan 9, 2020
Financial News

Aspect to engineer therapeutic tissues with $20M series A

...therapeutics. New investor Radical Ventures led the University of British Columbia spinout’s financing. Existing investors Pangaea...
BioCentury | Oct 20, 2017
Regulation

Realities of real-world evidence

...to treat chronic obstructive pulmonary disease (COPD), demonstrating the feasibility of premarket RWE research. (A) PANGAEA...
...target attainment at six months without documented symptomatic hypoglycemia 3,324 Sanofi (Euronext:SAN; NYSE:SNY) Jul 2018 PANGAEA...
BioCentury | May 30, 2016
Company News

Cancer Research UK, Pangaea Biotech deal

...Rac)-activated kinase (PAK) inhibitors for cancer. Both partners will be responsible for lead optimization, and Pangaea...
...future payments. The partners declined to disclose financial terms. Cancer Research UK , London, U.K. Pangaea...
BioCentury | Apr 15, 2013
Company News

Pangaea management update

Pangaea Pharmaceuticals Inc., Cambridge, Mass. Business: Cancer, Autoimmune/Inflammation, Infectious diseases/AIDS Hired: Mark Philip, Ph.D., as president and CEO; formerly president and CEO of Immuno-U.S. Inc. WIR Staff autoimmune cancer Infectious Inflammation...
BioCentury | Dec 20, 2010
Financial News

Semprus BioSciences completes venture financing

...12/13/10 Type: Venture financing Raised: $18 million Investors: SR One; Foundation Medical Partners; 5AM Ventures; Pangaea...
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Markers

...large-scale prospective study of transplant patients to identify candidates for a reduced regimen of immunosuppressants. Pangaea...
...Predicting allograft tolerance, page 7). SciBX 3(23); doi:10.1038/scibx.2010.719 Published online June 10, 2010 Patent pending; Pangaea...
BioCentury | Jun 10, 2010
Tools & Techniques

Predicting allograft tolerance

...that could help pinpoint transplant patients who may not need immunosuppressants. Miltenyi Biotec GmbH and Pangaea...
...said Pangaea CEO José Jimeno. "These patients will be more amenable to reducing immunosuppressant dosage." Pangaea...
...Bethesda, Md. King's College London , London, U.K. Miltenyi Biotec GmbH , Bergisch Gladbach, Germany Pangaea...
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Markers

...profile of tolerance and testing the effect of reduced dosing of immunosuppressants in those patients. Pangaea...
BioCentury | Mar 26, 2001
Company News

Infigen management update

...Wis. Business: Gene/Cell therapy Hired: Eric Postel as CFO, formerly senior partner and CFO at Pangaea...
BioCentury | Jun 28, 1999
Finance

It's all a matter of time

...of a capital infusion of CHF140 million ($93.7 million) in May, has added Zycos (formerly Pangaea...
Items per page:
1 - 10 of 24